FDA Approves First Drug for a Key Protein in Pancreatic Cancer

The FDA approved a new drug, daraxonrasib (Rasonque), on August 26, 2026 — the first targeted treatment for pancreatic cancer that has spread. A 500-patient trial funded by the maker found patients lived a median of 13.2 months versus 6.7 on chemotherapy. The drug blocks a protein called KRAS, long thought impossible to target, that drives most cases. Five-year survival is just 13%. The trial's company funding warrants independent confirmation.